# Iolyx Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/iolyx-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Burlingame, US
- Website: www.iolyx.com/
- Total disclosed funding: $15M
- Latest round: Series B (Dec 3, 2025)
- Investors on record: 2

## About

Iolyx Therapeutics, Inc., based in the US, specializes in innovative immunomodulatory therapies aimed at treating ocular diseases by targeting inflammation directly at its source.Founded in 2021 and headquartered in Burlingame, California, Iolyx Therapeutics, Inc. focuses on developing therapies for ocular conditions. The company has engaged in one funding deal as of December 3, 2025, raising USD 15 mn in a Series B round led by Frazier Life Sciences, with participation from GC&H Investments. This funding aims to support the preparation of ILYX-002 for Phase 3 trials and expand into autoimmune-related retinal diseases.Iolyx Therapeutics develops therapies targeting ocular diseases, including Dry Eye, Ocular Allergies, Rosacea, Uveitis, Age-related Macular Degeneration, Diabetic Retinopathy, and Posterior Uveitis. Their products provide tailored formulations for precise delivery, addressing limitations of traditional treatments. They primarily market their therapies in the United States, with plans for global expansion as they secure regulatory approvals.Iolyx Therapeutics generates revenue through direct sales of its proprietary therapeutics to healthcare providers and institutions specializing in ocular health. The company collaborates with medical providers and distributors to ensure product accessibility. Their revenue model relies on the sales of therapeutics, leveraging ongoing treatment needs for chronic conditions.Iolyx Therapeutics plans to utilize the recent Series B funding of USD 15 mn to advance its product pipeline, particularly preparing ILYX-002 for Phase 3 clinical trials. Additionally, the company aims to expand into autoimmune-related retinal diseases, targeting broader market access and product offerings in the coming years.

## Funding rounds

- Series B, Dec 3, 2025, $15M — GC&H Investments, Frazier Life Sciences

## Investors

- GC&H Investments (https://capitalatlas.ai/funds/gc-h-investments) — Series B
- Frazier Life Sciences — Series B